Board Member

Dr. Xiyan Li

Co-founder

Biography

“I hope that we help manage more serious diseases that are currently handled only with drugs.”

Since launch in October 2018, Dr. Li has led Filtricine from cell-based technology to clinical trial initiation. He and the cofounders incubated the company at IndieBio and secured seed financing led by True Ventures and SOSV. As an expert in cancer metabolism, Dr. Li discovered and patented Targeted Nutrients Deprivation while at Stanford University Medical School.  That patent was followed by two additional Filtricine patents. Dr. Li holds a PhD from the University of Maryland and trained with Dr. Mike Snyder at Yale and Stanford Universities.

Our Team

Dr. John Chant
CEO
Dr. Grace Xiaolu Yang
COO, VP of Research & Co-founder
Mike Partsuf
Senior Food Scientist
Emily Sinovic
Public Relations Consultant
Todd Lorenz
Clinical Development Consultant

Our Advisors

Dr. Mike P Snyder
Stanford University School of Medicine
Peter B Hutt
Senior Counsel at Covington & Burling LLP
Brad Barnes
Culinary Institute of America
Dr. Dariush Mozaffarian
Tufts University
Dr. Yung-Chi Cheng
Yale University School of Medicine
Dr. Danhua Xiao
Atlantic Health Metabolic Center
Dr. Joseph V Rodricks
Ramboll (formerly ENVIRON)
Alister Thomson
Bristol Myers Squibb (Former)
Jeff Depew
Sand Hill Angels
Dr. Wei Jiang
Medical Affairs at MorphoSys

Our Board of Directors

Dr. John Chant
CEO
Dr. Xiyan Li
Co-founder
Dr. Rami El Assal
Founding Partner at Boutique Venture Partners
Drew Lanza
Founding Partner at Berkeley Catalyst Fund
We are a clinical-stage biotechnology company based in the San Francisco Bay Area dedicated to developing novel food products for disease control.
© 2024 Filtricine, Inc. All Rights Reserved | by Wuilt